{
  "url": "https://struct.news/briefs/maze-turned-zero-revenue-into-20m-but-cash-burn-still-ran-at-54m",
  "title": "Maze turned zero revenue into $20M, but cash burn still ran at $54M",
  "summary": "Maze ended June with $202.6M in cash, down 23.4%, as R&D spending and diluted shares climbed.",
  "published_at": "2026-08-11T23:48:03.950459+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "Maze Therapeutics, Inc.",
    "ticker": "MAZE",
    "cik": "1193125",
    "sector": "Healthcare",
    "industry": "Biotechnology"
  },
  "source_filing": {
    "form": "10-Q",
    "filed": "2026-08-11",
    "accession": "0001193125-26-344903",
    "url": "https://www.sec.gov/Archives/edgar/data/1842295/000119312526344903/maze-20260630.htm"
  },
  "comparison_filing": {
    "form": "10-Q",
    "filed": "2025-08-12",
    "url": "https://www.sec.gov/Archives/edgar/data/1842295/000095017025107306/maze-20250630.htm"
  },
  "reported_figures": [
    {
      "group": "The filing in three numbers",
      "label": "Revenue",
      "value": 167500000,
      "display": "$167.5M",
      "unit": "usd",
      "period": "2024-12-31",
      "detail": null,
      "source": {
        "kind": "sec_filing",
        "label": "Filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-344903",
        "filing_date": "2026-08-11"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Operating margin",
      "value": 34.379701492537315,
      "display": "+34.4%",
      "unit": "percent",
      "period": "2024-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-344903",
        "filing_date": "2026-08-11"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Net margin",
      "value": 31.18268656716418,
      "display": "+31.2%",
      "unit": "percent",
      "period": "2024-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-344903",
        "filing_date": "2026-08-11"
      }
    }
  ],
  "watch_next": [
    {
      "type": "product_pipeline",
      "statement": "Research and development spending rose as Maze advanced MZE829 and expanded discovery work.",
      "importance": "medium",
      "evidence": "The increase of $13.4 million between the comparative six month periods was primarily due to an increase of $7.9 million in personnel-related costs due to an increase in headcount and higher non-cash stock-based compensation expense, an increase of $5.7 million related to progression of our clinical development of the MZE829 program",
      "source_date": "2026-08-11"
    }
  ],
  "related_tickers": [
    "MAZE"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}